For a woman navigating the hormonal fluctuations of fertility treatment or menopause, the standard of care is a series of snapshots. It is a calendar punctuated by clinic visits and blood draws, each vial offering a single, static data point on hormones like estradiol. The intervals between those points are a blind spot, a gap in the clinical picture where critical shifts can occur unnoticed. Persperity Health, a Caltech spinout founded in 2024, is betting that a continuous stream of data from a patient’s own sweat can fill that gap, offering a more humane and informative path to managing hormonal health [Persperity Health].
The Caltech wedge
The company’s entire premise rests on technology licensed exclusively from the lab of Dr. Wei Gao at Caltech. The core innovation is an aptamer-based biosensor, engineered to detect hormone molecules in sweat at subpicomolar concentrations, a level of precision the company claims is comparable to clinical blood tests [Persperity Health]. Worn as a non-invasive patch, the sensor is designed to stream data in real time to a companion app, creating what Persperity calls “hormone intelligence.” This continuous monitoring is the primary wedge against the established, intermittent standard of blood testing. For conditions like in vitro fertilization (IVF), where estradiol levels must be tracked closely to optimize medication timing, the promise is a more responsive protocol that could improve outcomes and reduce costs [Perplexity Sonar Pro Brief].
A team built for translation
Persperity’s founding team reflects a deliberate blend of deep technical expertise and clinical application focus. Dr. Wei Gao, the inventor, serves as a co-founder, providing a direct conduit to the underlying science. Co-founder and CEO Shiv Shukla leads the commercial effort. The team is rounded out by co-founders Dr. Heather Lukas and biosensor engineer Michelle Wong, who holds a master’s from UCSD and has diagnostic startup experience [LinkedIn, 2026] [Finsmes]. Crucially, the company has enlisted Dr. Pauline Maki, a noted researcher in women’s cognition and menopause, as a clinical collaborator. This structure suggests a clear-eyed focus on moving from lab prototype to a tool validated for real-world women’s health conditions, from irregular cycles to menopausal symptom management [Finsmes].
The path to a regulated product
As with any novel diagnostic hardware, the road ahead is defined by regulatory milestones. Persperity is in the pre-seed, R&D phase, having raised $1 million in late 2024 from a syndicate led by Freeflow Ventures and including Caltech, Wilson Hill Ventures, Heritage Group, ATMA Capital, and the Merkin Family Office [PR Newswire, October 2024]. That capital is earmarked for accelerating development of the sweat-sensing platform. The next critical steps will involve generating the clinical data required for FDA clearance, a process that will test the sensor’s accuracy and reliability in target populations. The company is a resident at LA BioSpace, an incubator environment suited for this early-stage biotech work.
| Founder / Lead | Role | Key Background |
|---|---|---|
| Shiv Shukla | Co-Founder & CEO | Leading commercial translation. |
| Dr. Wei Gao | Co-Founder | Caltech researcher; inventor of core sweat-sensing tech. |
| Dr. Heather Lukas | Co-Founder | Focus on women’s health applications. |
| Michelle Wong | Co-Founder | Biosensor engineer; MS from UCSD; diagnostic startup experience. |
| Dr. Pauline Maki | Clinical Collaborator | NIH-funded researcher in menopause, cognition, and mood. |
Where the wheels could come off
The ambition is significant, and so are the hurdles. Persperity operates in a space where patient safety and data integrity are paramount, and regulatory scrutiny will be intense. The most credible risk is not technological competition,the sweat-based approach is distinctive,but the sheer difficulty of proving clinical utility and navigating the FDA’s de novo or 510(k) pathway for a novel diagnostic. Furthermore, sweat composition can be influenced by factors like hydration, diet, and skin temperature, which the platform’s algorithms must account for to ensure consistent, clinical-grade readings. The company’s answer lies in its exclusive Caltech IP and the clinical partnership with researchers like Dr. Maki, which are assets for designing robust validation studies. The pre-seed round provides runway, but subsequent financing will likely hinge on demonstrating clear progress toward these regulatory benchmarks.
The next twelve months
For Persperity, the immediate future is about moving from concept to credible prototype. Key milestones to watch will include the initiation of pilot clinical studies, likely focusing on a specific indication such as IVF hormone monitoring. A successful pilot would set the stage for a larger seed round to fund more comprehensive trials. The company must also begin to articulate a clearer commercial strategy, determining whether its initial route will be direct-to-consumer, through fertility clinics, or a hybrid model. Each path carries different regulatory and market challenges.
The patient population here is clearly defined: women managing fertility, including those undergoing IVF, and women navigating the transition through menopause. For them, the current standard of care is often frustratingly episodic. It involves scheduling and attending blood draws, waiting for lab results, and making decisions based on data that is already days old. Persperity’s vision is to make that process continuous, passive, and integrated into daily life. If the technology performs as promised under regulatory review, it wouldn’t just be a new device; it would represent a fundamental shift in how hormonal health is measured and managed, turning a chronicle of snapshots into a real-time narrative.
Sources
- [Finsmes, 2024] Persperity Health Raises $1M in Pre-Seed Funding | https://www.finsmes.com/2024/11/persperity-health-raises-1m-in-pre-seed-funding.html
- [LinkedIn, 2026] Michelle Wong - Nventric, Inc. | https://www.linkedin.com/in/wanchimichelle-wong/
- [Perplexity Sonar Pro Brief] Persperity Health Company Brief | [No URL]
- [Persperity Health] Revolutionizing Women’s Health: Persperity Health’s Breakthrough in Real-Time Hormone Monitoring | https://persperityhealth.com/revolutionizing-womens-health-persperity-healths-breakthrough-in-real-time-hormone-monitoring/
- [PR Newswire, October 2024] Persperity Health Raises $1 Million in Pre-Seed Funding | [No URL]